Notícias e Atividades da Ferring Pharmaceuticals USA

A Ferring Pharmaceuticals USA pertence à Ferring Pharmaceuticals. Ferring Pharmaceuticals tem presença direta em 3 países.

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Ferring Pharmaceuticals USA

• Brent Ragans, President
• Leonardo Silva, Vice President, Global Chief Compliance & Privacy ...
• Purvi Tailor, Vice President, Human Resources

Recentes movimentos de executivos em Ferring Pharmaceuticals

• Krishnakumar N, ingressou na Companhia como Director, External Manufacturing Network  (Notícia publicada em 13 de abril de 2026).
• Armin Metzger, Executive Vice President and Chief Technical Operations Officer, deixará a Companhia em 1 de abr. de 2026  (Notícia publicada em 27 de março de 2026).
• Luzi von Bidder, Director, deixou a Companhia  (Notícia publicada em 27 de março de 2026).

Clique aqui para ver outras movimentos em Ferring Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Ferring Pharmaceuticals USA.

Ferring Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Ferring Pharmaceuticals USA

• Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program - Ferring Pharmaceuticals USA
• Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation - Ferring Pharmaceuticals USA
• Ferring Appreciates the Support of New Jersey and Minnesota as They Issue Proclamations Recognizing November as C. Difficile Infection Awareness Month for Fifth Consecutive Year - Ferring Pharmaceuticals USA
• Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024 - Ferring Pharmaceuticals USA
• Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress - Ferring Pharmaceuticals USA
• Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024 - Ferring Pharmaceuticals USA
• Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024 - Ferring Pharmaceuticals USA
• Ferring to Present New Data Analysis at NASS 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation - Ferring Pharmaceuticals USA
• Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024 - Ferring Pharmaceuticals USA
• Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation - Ferring Pharmaceuticals USA
• View more press releases Close

Redes sociais sobre Ferring Pharmaceuticals USA

• Ferring Pharmaceuticals USA na Wikipedia, Google News e Yahoo Finance
• Ferring Pharmaceuticals USA na LinkedIn, X (Twitter) e YouTube